MacroGenics To Initiate Phase II Trial Of Teplizumab For Type 1 Diabetes
This article was originally published in The Pink Sheet Daily
Executive Summary
CEO discusses details of the study and future areas of research in an interview with “The Pink Sheet” DAILY.
You may also be interested in...
Lilly Sweet On MacroGenics’ Novel Diabetes Drug Teplizumab
Anti-CD3 monoclonal antibody is now in a pivotal Phase II/III clinical trial for treating underlying disease in type 1 diabetes, Lilly tells “The Pink Sheet” DAILY.
Lilly Sweet On MacroGenics’ Novel Diabetes Drug Teplizumab
Anti-CD3 monoclonal antibody is now in a pivotal Phase II/III clinical trial for treating underlying disease in type 1 diabetes, Lilly tells “The Pink Sheet” DAILY.
PDL Focus Remains Nuvion, But 2007 Could Include Several Significant Deals
The biotech is “aggressively” seeking potential in-licensing opportunities and hopes to partner its heart failure agent ularitide in 2007.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: